Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States.
| Revenue (Most Recent Fiscal Year) | $0.21M |
| Net Income (Most Recent Fiscal Year) | $-12.55M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 9.05 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -67.45% |
| Return on Assets (Trailing 12 Months) | -59.18% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.45 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.45 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.59 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.07 |
| Earnings per Share (Most Recent Fiscal Year) | $-0.39 |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.35 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 32.92M |
| Free Float | 24.59M |
| Market Capitalization | $142.53M |
| Average Volume (Last 20 Days) | 0.29M |
| Beta (Past 60 Months) | 0.69 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 25.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 29.13% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |